Viatris Price to Free Cash Flow Ratio 2010-2024 | VTRS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Viatris average price to free cash flow ratio for 2023 was 5.33, a 22.25% decline from 2022.
Viatris average price to free cash flow ratio for 2022 was 4.36, a 43.89% increase from 2021.
Viatris average price to free cash flow ratio for 2021 was 7.77, a 31.92% decline from 2020.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Viatris average price to free cash flow ratio for 2023 was 5.33, a 22.25% decline from 2022.
Viatris average price to free cash flow ratio for 2022 was 4.36, a 43.89% increase from 2021.
Viatris average price to free cash flow ratio for 2021 was 7.77, a 31.92% decline from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$98B
Cencora (COR)	$48.9B
DiDi Global (DIDIY)	$23.6B
ICON (ICLR)	$17.7B
Natera (NTRA)	$16.6B
Avantor (AVTR)	$15.4B
Revvity (RVTY)	$14.9B
BioMerieux (BMXMF)	$13.1B
CochLear (CHEOY)	$12.6B
Solventum (SOLV)	$12.5B
Medpace Holdings (MEDP)	$11.3B
Charles River Laboratories (CRL)	$11B
Doximity (DOCS)	$10.8B
HealthEquity (HQY)	$8.6B
Sonic Healthcare (SKHHY)	$8.5B
Bausch + Lomb (BLCO)	$7B
Life Times (LTH)	$5.2B
Sotera Health (SHC)	$4.6B
Organon (OGN)	$4.1B
Surgery Partners (SGRY)	$3.9B
BrightSpring Health Services (BTSG)	$3.4B
PACS (PACS)	$3.3B
Alignment Healthcare (ALHC)	$2.6B
Concentras Parent (CON)	$2.5B
Ardent Health Partners (ARDT)	$2.3B
Premier (PINC)	$2.3B
GeneDx Holdings (WGS)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GoodRx Holdings (GDRX)	$1.9B
Teladoc Health (TDOC)	$1.6B